In the Pipeline
In the Pipeline
• AnorMED has initiated a Phase II clinical trial to evaluate the potential of AMD-3100 as a new agent for stem cell transplantation in cancer patients. In this study, AMD-3100 will be given in combination with the standard agent, G-CSF or Neupogen, to patients with multiple myeloma and non-Hodgkin’s lymphoma.
• OncoGenex Technologies and Isis Pharmaceuticals have announced the initiation of a Phase I clinical trial of OGX-011 in patients with prostate cancer. OGX-011 is an antisense drug being developed to sensitize tumors resistant to existing treatments such as chemotherapy, hormone ablation therapy, and radiation therapy.
• VaxGen has announced that the U.S. Food and Drug Administration (FDA) has designated the company’s HIV/AIDS vaccine candidates, AIDSVAX B/B and AIDSVAX B/E (rgp120), fast-track products for prevention of HIV infection.
• Millennium Pharmaceuticals has initiated a Phase I clinical trial of MLN1202, a humanized monoclonal antibody that blocks the chemokine receptor CCR2. MLN1202 is being developed as a potential treatment for patients with rheumatoid arthritis and possibly other inflammatory diseases.
• Pain Therapeutics has initiated a pilot clinical study of a proprietary drug in patients who suffer from irritable bowel syndrome.
• Acologix has initiated a Phase I clinical study of its lead compound AC-100 (Dentonin) to support its primary indication, osteoporosis.
• DOV Pharmaceutical has initiated a Phase III clinical trial investigating bicifadine, the company’s non-narcotic analgesic, in the treatment of moderate-to-severe post-surgical dental pain.
The following drugs have not yet received FDA approval.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.